| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.16 | 0.007 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.088 | 0.007 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.087 | 0.007 |
| mRNA | IOX2 | GDSC1000 | pan-cancer | AAC | -0.089 | 0.007 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.16 | 0.007 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.008 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.088 | 0.009 |
| mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.009 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.1 | 0.009 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.009 |